Prednisolone

• Effect of Alpha-1 Antitrypsin Supplementation in Alcohol-Associated Hepatitis-A prospective Pilot Study Recruiting
  2024-515794-99-00 Phase II 1 country Medizinische Universitaet Innsbruck
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Recruiting
  2024-517422-25-00 Phase III 12 countries Celgene Corp.
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 Phase II 5 countries Merck Sharp & Dohme LLC
• Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub… Recruiting
  2024-510893-25-00 Phase III 1 country Institut De Cancerologie De L Ouest
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 Phase III 11 countries Merck Sharp & Dohme LLC
• An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting
  2024-514648-10-00 Phase III 6 countries Pfizer Inc.
• A trial to learn if AZD0486 alone or with other anticancer drugs is safe and works in adults with certain blood cancers Recruiting
  2024-515034-33-00 Phase I/II 5 countries AstraZeneca AB
• Prednisone treatment in acute interstitial nephritis (PRAISE) Recruiting
  2024-520299-86-00 Phase IV 1 country Region Midtjylland
• A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting
  2023-509230-19-00 Phase I (FiH) 3 countries Eikon Therapeutics Inc.
• Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION) Recruiting
  2023-505990-34-00 Phase II 1 country Karolinska University Hospital
• Efficacy and safety trial of GNT0003 following imlifidase pre-treatment in participants aged 16 years and older with severe Crigler-Najjar s… Recruiting
  2023-510405-18-00 Phase II 1 country Genethon
• QUIDOSE. Randomized controlled trial testing the efficacy of hydroxychloroquine combined with low dose corticosteroid therapy in pulmonary s… Recruiting
  2024-516101-23-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll… Recruiting
  2023-508520-36-00 Phase III 7 countries Allergy Therapeutics (UK) Limited
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly… Recruiting
  2023-505377-32-00 Phase III 1 country Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Generalized Myasthenia Gravis Recruiting
  2023-509892-17-00 Phase II/III 1 country Kyverna Therapeutics Inc.
• “Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent n… Recruiting
  2023-505112-38-00 Phase III/IV 1 country Assistance Publique Hopitaux De Paris
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting
  2023-504899-25-00 Phase III 14 countries Merck Sharp & Dohme LLC
• RECOVERY Recruiting
  2023-507441-29-00 Phase III 9 countries University Of Oxford
• PREMI trial Recruiting
  2023-503220-76-01 Phase IV 1 country Leiden University Medical Center
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 Phase III 8 countries Regeneron Pharmaceuticals Inc.
• Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months … Recruiting
  2022-502332-39-00 Phase II 2 countries Heidelberg University Hospital AöR
• CITAR - Comparison of the efficacy and safety of early use of IL-6R blockade with tocilizumab in combination with short-term glucocorticoids… Recruiting
  2022-501130-33-00 Phase II 2 countries Karolinska University Hospital
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III 19 countries Argenx
• The iCaD Study Recruiting
  2022-503026-12-00 Phase III 1 country Odense University Hospital

Showing 25–48 of 117 trials